Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

7th Eurasian Hematology Oncology Summit
T

2020 Update on MPNs: What Is the Risk Adapted Management in PV? Is Ropeginterferon Alfa-2b Effective in Inducing CHR? Can We Achieve Both HCT Control and Spleen Response With Ruxolitinib?

By 7th Eurasian Hematology Oncology Summit FEATURING Tariq Mughal
By 7th Eurasian Hematology Oncology Summit FEATURING Tariq Mughal
117 views
December 10, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

19:39
Pfizer Hematology

The First Treatment Choice Matters

Feat. A. Ip

Featured Video

15:43
Incyte

Importance of Early Management of Patients with Myelofibrosis (MF)

Feat. P. Bose, R. Rampal
MDS and MPN
15:05

2020 Updates on MDS: Is Deferasirox Beneficial for EFS? Can We Achie…

7th Eurasian Hematology Oncology Summit

G. Garcia-Manero

168 views
18:36

2020 Update on High-Risk MDS: Does Aza Improve OS/ORR? How to Minimi…

7th Eurasian Hematology Oncology Summit

M. Mittelman

64 views
11:32

2020 Updates on MDS: Role of Prognostic Models, Cytogenetics, IPSS, …

7th Eurasian Hematology Oncology Summit

G. Garcia-Manero

96 views
26:20

2020 Update on MPNs: What Is the Risk Adapted Management in PV? Is R…

7th Eurasian Hematology Oncology Summit

T. Mughal

117 views